uniQure N.V. $QURE Position Decreased by Integral Health Asset Management LLC

Integral Health Asset Management LLC decreased its position in uniQure N.V. (NASDAQ:QURE) by 55.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 600,000 shares of the biotechnology company’s stock after selling 750,000 shares during the period. uniQure makes up about 2.4% of Integral Health Asset Management LLC’s portfolio, making the stock its 6th biggest holding. Integral Health Asset Management LLC owned about 1.09% of uniQure worth $35,022,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Private Trust Co. NA acquired a new position in shares of uniQure in the third quarter valued at about $28,000. Jones Financial Companies Lllp raised its stake in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,538 shares during the period. Knott David M Jr acquired a new stake in shares of uniQure during the third quarter worth about $117,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in uniQure in the second quarter valued at approximately $215,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. Stifel Nicolaus set a $14.00 price objective on shares of uniQure in a report on Monday, March 2nd. Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $12.00 to $35.00 in a report on Wednesday. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $15.00 to $60.00 in a research note on Monday, March 9th. Finally, Chardan Capital boosted their target price on shares of uniQure from $16.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, March 9th. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $43.25.

Insider Activity

In other uniQure news, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the transaction, the director owned 32,342 shares in the company, valued at approximately $796,260.04. This represents a 44.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 14,581 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $132,103.86. Following the sale, the chief executive officer directly owned 660,658 shares in the company, valued at approximately $5,985,561.48. The trade was a 2.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 81,399 shares of company stock valued at $1,527,645 in the last three months. Corporate insiders own 4.79% of the company’s stock.

uniQure Trading Down 8.3%

Shares of NASDAQ:QURE opened at $15.53 on Friday. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. uniQure N.V. has a 12-month low of $7.76 and a 12-month high of $71.50. The business has a 50 day moving average of $21.37 and a two-hundred day moving average of $29.49. The company has a market capitalization of $971.09 million, a PE ratio of -4.50 and a beta of 0.73.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to analysts’ expectations of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. As a group, analysts forecast that uniQure N.V. will post -3.75 EPS for the current year.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and maintained a $70 price target on QURE, giving some institutional-support context despite lowered estimates. HC Wainwright Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE)
• Neutral Sentiment: Market/opinion coverage is running — e.g., a Seeking Alpha piece frames uniQure’s situation as complex and worth reading for background, but it does not add new regulatory facts. A Unique Situation For UniQure
• Negative Sentiment: FDA reportedly issued an unprecedented public rebuke alleging uniQure pushed “distorted” or “manipulated” data related to AMT‑130; plaintiffs’ firms are citing that as the basis to expand securities investigations — a major regulatory risk for the company’s lead program and valuation. QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data …
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs in securities class actions (class period: Sept. 24–Oct. 31, 2025) and have set an April 13, 2026 lead‑plaintiff filing deadline — increasing legal and settlement-tail risk. Representative filings/alerts include Kessler Topaz, Pomerantz and Schall. uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz … QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit …
• Negative Sentiment: HC Wainwright materially cut near‑ and long‑term EPS forecasts (Q1–Q4 2026 and FY2026–FY2030), reducing future earnings visibility and implying a slower timeline to commercialization/profitability despite the Buy rating. That revision increases downside risk to current valuation. uniQure (NASDAQ: QURE) analyst/estimate coverage — MarketBeat

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.